Chun‐Hwa Chen

发表

Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.

Sing-Yi Wang, Mohane Selvaraj Coumar, Yu-Sheng Chao, 2010, Journal of medicinal chemistry.

3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

C. Chen, Y. Chao, J. Hsu, 2012, Bioorganic & medicinal chemistry letters.

Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.

H. Hsieh, C. Chen, Y. Chao, 2013, Journal of medicinal chemistry.

Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.

P. Lyu, Yi-Hui Peng, H. Hsieh, 2013, Journal of medicinal chemistry.

Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.

Yi-Hui Peng, A. Yueh, J. Hsu, 2015, Journal of medicinal chemistry.

Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.

H. Hsieh, J. Hsu, M. Coumar, 2020, Bioorganic chemistry.

Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.

Wen-Chieh Wang, Wen-Hsing Lin, Hsing-Pang Hsieh, 2016, European journal of medicinal chemistry.

Facile Identification of Dual FLT3–Aurora A Inhibitors: A Computer‐Guided Drug Design Approach

H. Hsieh, J. Hsu, Yi-Yu Ke, 2014, ChemMedChem.

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.

Yi-Hui Peng, H. Hsieh, C. Chen, 2019, Journal of medicinal chemistry.

Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

Santhosh Kumar Chittimalla, Yi-Hui Peng, H. Hsieh, 2010, Journal of medicinal chemistry.

Identification, SAR Studies, and X‐ray Co‐crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor

H. Hsieh, Y. Chao, J. Hsu, 2010, ChemMedChem.

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

Yung Chang Hsu, H. Hsieh, J. Hsu, 2015, Scientific Reports.

Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation

Yung Chang Hsu, C. Chen, J. Hsu, 2016, Oncotarget.

Anchor-based classification and type-C inhibitors for tyrosine kinases

J. Hsu, Jinn-Moon Yang, Y. Chiu, 2015, Scientific Reports.

Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.

C. Chen, Y. Chao, J. Hsu, 2015, European journal of medicinal chemistry.

Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer

H. Hsieh, C. Chen, T. Lien, 2023, Journal of medicinal chemistry.

Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer

C. Chen, Y. Chao, T. Yeh, 2014, PloS one.

Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.

Mohane Selvaraj Coumar, Yu-Sheng Chao, Su-Ying Wu, 2009, Journal of medicinal chemistry.

3D‐QSAR‐Assisted Drug Design: Identification of a Potent Quinazoline‐Based Aurora Kinase Inhibitor

Yung Chang Hsu, H. Hsieh, Y. Chao, 2013, ChemMedChem.

Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).

C. Chen, Y. Chao, J. Hsu, 2013, Bioorganic & medicinal chemistry.

A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.

H. Hsieh, T. Lien, Y. Chao, 2012, Anticancer research.